Biogen advances research in SMA, with new data at AAN 2021
US biotech major Biogen (Nasdaq: BIIB) today announced new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease.
These data are being presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22.
“Biogen is humbled that we were pioneers in developing the first treatment for SMA, along with our collaboration partners Ionis Pharmaceuticals. We continue to be driven by the pursuit of better outcomes for patients, including exploring the potential of a higher dose of Spinraza in the DEVOTE study, in addition to initiating the RESPOND study,” said Dr Alfred Sandrock Jr, head of R&D at Biogen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze